Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic...

por Koser, Andras, Westerman, Jan, Sharma, Sanjay, Emmett, Amanda, Crater, Glenn D
Publicado 2010

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk

por Covelli, Henry, Pek, Bonavuth, Schenkenberger, Isabelle, Scott-Wilson, Catherine, Emmett, Amanda, Crim, Courtney
Publicado en Int J Chron Obstruct Pulmon Dis (2015)

Disease severity and symptoms among patients receiving monotherapy for COPD

por Dransfield, Mark T, Bailey, William, Crater, Glenn, Emmett, Amanda, O'Dell, Dianne M, Yawn, Barbara
Publicado en Prim Care Respir J (2011)

A Patient-Centered Walking Program for COPD

por Bender, Bruce G., Depew, Ann, Emmett, Amanda, Goelz, Kelly, Make, Barry, Sharma, Sanjay, Underwood, Jennifer, Stempel, David
Publicado en Chronic Obstr Pulm Dis (2016)

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD

por Crim, Courtney, Gotfried, Mark, Spangenthal, Selwyn, Watkins, Michael, Emmett, Amanda, Crawford, Catriona, Baidoo, Charlotte, Castro-Santamaria, Ramiro
Publicado en BMC Pulm Med (2020)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation

por Ohar, Jill A, Crater, Glenn D, Emmett, Amanda, Ferro, Thomas J, Morris, Andrea N, Raphiou, Ibrahim, Sriram, Peruvemba S, Dransfield, Mark T
Publicado 2014

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts

por Forns, Xavier, Feld, Jordan J., Dylla, Douglas E., Pol, Stanislas, Chayama, Kazuaki, Hou, Jinlin, Heo, Jeong, Lampertico, Pietro, Brown, Ashley, Bondin, Mark, Tatsch, Fernando, Burroughs, Margaret, Marcinak, John, Zhang, Zhenzhen, Emmett, Amanda, Gordon, Stuart C., Jacobson, Ira M.
Publicado en Adv Ther (2021)